Zobrazeno 1 - 10
of 30
pro vyhledávání: '"S. V. Glagolev"'
Autor:
l. V. Fedina, i. N. Sychev, K. V. Mirzaev, A. V. Vardanyan, S. V. Glagolev, A. A. Kachanova, P. O. Bochkov, R. V. Shevchenko, S. N. Tuchkova, I. V. Sychev, S. P. Abdullaev, D A. Sychev
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 20, Iss 1, Pp 19-26 (2024)
Aim. The aim of our study was to investigate the influence of polymorphic markers of CYP3A4*22 CYP3A4*22 (c.522-191C>T, rs35599367), CYP3A5*3 (c.219237A>G, rs776746), ABCB1 rs1045642 (c.3435T>C) and rs4148738 (c.2692-2236C>T) genes on the plasma conc
Externí odkaz:
https://doaj.org/article/895693a579cb4ad08184d9190f32a514
Hospital consumption of direct oral anticoagulants in regions of the Russian Federation in 2017–2022
Publikováno v:
Фармация и фармакология (Пятигорск), Vol 11, Iss 6, Pp 461-470 (2024)
The aim of the study was to investigate the dynamics of inpatient consumption of direct oral anticoagulants in different regions of the Russian Federation for the period from 2017 to 2022.Materials and methods. This study is a non-interventional, ret
Externí odkaz:
https://doaj.org/article/644bef11a8be43029e56a085b2a8a80d
Autor:
N. A. Shatalova, D. A. Sychev, K. B. Mirzaev, A. I. Kochetkov, E. Yu. Ebzeeva, V. B. Dashabylova, P. O. Bochkov, S. N. Tuchkova, S. V. Glagolev
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 19, Iss 5, Pp 470-478 (2023)
Aim. To study the possible relationship between polymorphic variants of ABCB1 (rs2032582, rs1045642, rs1128503), CYP3A5 (rs776746), CYP3A4 (rs35599367) and CYP2J2 (rs890293) genes with residual equilibrium concentrations (Cmin,ss) of rivaroxaban in p
Externí odkaz:
https://doaj.org/article/9a8bd307ca844343b2cc8835a800342f
Autor:
A. V. Kryukov, A. S. Zhiryakova, Yu. V. Shevchuk, A. V. Matveev, V. I. Vechorko, O. V. Averkov, S. V. Glagolev, I. I. Temirbulatov, K. B. Mirzaev, N. P. Denisenko, Sh. P. Abdullaev, D. A. Sychev
Publikováno v:
Безопасность и риск фармакотерапии, Vol 10, Iss 4, Pp 326-344 (2022)
The safety of COVID-19 pharmacotherapy is a relevant issue, first of all, because of the current lack of experience with using particular medicinal products and with off-label prescribing. The aim of the study was to analyse information on potential
Externí odkaz:
https://doaj.org/article/5d9ff01bf50b46dfb11a1965a596882f
Publikováno v:
Безопасность и риск фармакотерапии, Vol 0, Iss 3, Pp 11-14 (2022)
The article presents recommendations for doctors, pharmacists, developers and manufacturers on how to prepare and report to the regulatory ofthe Russian Federation individual case safety reports of adverse drug reactions,unefficiency or adverse drug
Externí odkaz:
https://doaj.org/article/57869b4f00b34c0cb834148194223135
Autor:
A. V. Philippova, A. S. Kolbin, E. V. Verbitskaya, S. V. Glagolev, V. A. Polivanov, V. I. Mazurov, R. R. Samigullina
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 3, Pp 44-52 (2020)
Success in practical rheumatology of the latest decade achieved mainly due to monoclonal antibodies (MABs) appearance in routine medical practice. At the same time, the experience of practical application of MABs is limited both by observation period
Externí odkaz:
https://doaj.org/article/72820a4596e84a109fabdd2977836ad6
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 2, Pp 75-84 (2019)
Monoclonal antibodies are highly effective medications, which made a breakthrough in medicine. Taking into consideration the properties of monoclonal antibodies safety plays a key role in “risk-benefit” assessment. For monoclonal antibodies this
Externí odkaz:
https://doaj.org/article/a63433537fe347d8a64e1da655b57c2c
Autor:
B. K. Romanov, Yu. V. Olefir, R. N. Alyautdin, S. V. Glagolev, V. A. Polivanov, L. I. Ilienko, S. P. Alpatov, N. V. Bogush, N. M. Buyanova, I. V. Ganshina, G. O. Dibirova, N. B. Dmitrieva, I. B. Zhukova, E. V. Kalinina, A. V. Kirillova, N. M. Kiseleva, G. V. Kukushkin, T. I. Leonteva, M. L. Maximov, E. V. Markina, S. E. Mileshina, D. E. Yurov
Publikováno v:
Безопасность и риск фармакотерапии, Vol 7, Iss 2, Pp 57-64 (2019)
The review article presents a summary of adverse drug reactions (ADR) in children, information about which was received in 1968–2018 in the International database VigiBase (Uppsala monitoring center, UMC). Of the 18.4 million Individual Safety Case
Externí odkaz:
https://doaj.org/article/0c26d75242ad4f34bddd5bcb2856efec
Autor:
N. Yu. Velts, T. M. Bukatina, E. O. Zhuravleva, G. V. Kutekhova, M. A. Darmostukova, Yu. V. Olefir, B. K. Romanov, S. V. Glagolev, V. A. Polivanov
Publikováno v:
Безопасность и риск фармакотерапии, Vol 6, Iss 3, Pp 123-129 (2018)
Non-steroidal anti-inflammatory drugs (NSAIDs) are liders in selling both in the Russian Federation and worldwide. The combination of analgesic, anti-inflammatory and antipyretic effects make the drugs of this group very popular in patients with vari
Externí odkaz:
https://doaj.org/article/b3869af2c9fe40c2b3003e88c81032d6
Publikováno v:
Безопасность и риск фармакотерапии, Vol 6, Iss 1, Pp 6-10 (2018)
This article is a continuation of the publication «Standard form of a Periodic safety update report» in the previous issue of the journal. This article recommendations for the preparation of Periodic safety update report (PSUR) to ensure the develo
Externí odkaz:
https://doaj.org/article/dce02aa5e4a24b85a0929a80cdc8eceb